Global Hypertrophic Cardiomyopathy HCM Therapeutics Market Report 2024

Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2023 - By Drug Type (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types), By Device Type (Defibrillators, Pacemakers, Other Device Types), By End User (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : July 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Hypertrophic Cardiomyopathy (HCM) Therapeutics Global Market Report 2023

Proud Members Of

checkslacipN checkaoirsN checkscipN

Hypertrophic cardiomyopathy (HCM) therapeutics refers to a treatment of a condition in which the heart muscle becomes abnormally thick or hypertrophied. The thickening heart muscle makes the heart ineffective at pumping blood. Hypertrophic cardiomyopathy (HCM) therapeutics aim to reduce symptoms and guard against sudden cardiac death in high-risk patients.

The main drug types of hypertrophic cardiomyopathy (HCM) therapeutics are antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, calcium channel blockers and others. Antiarrhythmic agents are medications used to treat abnormal heart rhythms, or arrhythmias. The device types involved are defibrillators, pacemakers and others that are used in hospitals and clinics.

The global hypertrophic cardiomyopathy (HCM) therapeutics market is segmented -

1) By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types

2) By Device Type: Defibrillators, Pacemakers, Other Device Types

3) By End User: Hospitals, Clinics

The global hypertrophic cardiomyopathy (HCM) therapeutics market size is expected to grow from $1.26 billion in 2022 to $1.30 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hypertrophic cardiomyopathy (HCM) therapeutics market size is expected to reach $1.43 billion in 2027 at a CAGR of 2.4%.

Increasing incidence of cardiovascular diseases (CVD) is expected to propel the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular disease (CVD) is a condition that affects the heart or blood vessels. Cardiovascular diseases include heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block that require long-term monitoring. The primary need for therapeutics treatment for hypertrophic cardiomyopathy aims to alleviate symptoms and avoid sudden cardiac death in high-risk patients. For instance, according to the October 2022 report of the Center For Disease Control and Prevention (CDCP), a US-based national public health agency, in the United States, one person dies from cardiovascular disease every 36 seconds, and CVD is responsible for nearly 836,546 deaths in the United States alone in 2021. In 2020, approximately 697,000 people in the United States died from heart disease, with adults under the age of 65 accounting for roughly two-tenths of all CAD deaths. Therefore, the increasing incidence of cardiovascular diseases (CVD) drives the hypertrophic cardiomyopathy (HCM) therapeutics market.

Major players in the hypertrophic cardiomyopathy (HCM) therapeutics market are Merck & Co. Inc, Pfizer Inc, Sanofi S.A., Teva Pharmaceutical Industries Ltd, Novartis AG, Astra Zeneca Plc, Gilead Sciences Inc, Bayer AG, Correvio Pharma Corp, Abbott Laboratories Inc, Advanz Pharma Corp, Lupin limited, Myokardia Inc, Boston Scientific Corporation, Bristol Myers Squibb, Johnson & Johnson, and Medtronic Plc.

Product innovations are the key trend gaining popularity in the hypertrophic cardiomyopathy (HCM) therapeutics market. Major companies operating in the cardiomyopathy therapeutics sector are focused on developing new innovative products to strengthen their position in the market. For instance, in April 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, launched Camzyos (mavacamten), an oral small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of heart diastolic dysfunction. Camzyos (mavacamten) was approved by the US Food and Drug Administration (FDA) for the treatment of adults with symptomatic class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor of cardiac myosin that targets the underlying pathophysiology of obstructive HCM. Camzyos controls the number of myosin heads that can enter "on actin" (power-generating) states.

In May 2020, Bristol Myers Squibb, a US-based pharmaceutical company acquired Myokardia for $13.1 billion. Through this acquisition, Bristol-Myers Squibb gains Mavacamten, a potential first-in-class cardiovascular medicine from Myokardia for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Further, Bristol-Myers Squibb intends to examine the full potential of Mavacamten in additional indications, including non-obstructive HCM, as well as develop MyoKardia's promising pipeline of novel compounds, which includes two clinical-stage therapeutics for cardiovascular diseases, Danicamtiv (formerly MYK-491) and MYK-224. Myokardia is a US-based clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases.

North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the global hypertrophic cardiomyopathy (HCM) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypertrophic cardiomyopathy (HCM) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The hypertrophic cardiomyopathy (HCM) therapeutics market consists of revenues earned by entities by providing progressive disease management, physical therapy (PT), occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy (HCM) therapeutics market also consists of sales of disopyramide, wearable heart monitoring devices and cardiac rhythm management (CRM) devices which are used in providing hypertrophic cardiomyopathy (HCM) therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The hypertrophic cardiomyopathy (HCM) therapeutics market research report is one of a series of new reports from The Business Research Company that provides hypertrophic cardiomyopathy (HCM) therapeutics market statistics, including hypertrophic cardiomyopathy (HCM) therapeutics industry global market size, regional shares, competitors with hypertrophic cardiomyopathy (HCM) therapeutics market share, detailed hypertrophic cardiomyopathy (HCM) therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hypertrophic cardiomyopathy (HCM) therapeutics industry. This hypertrophic cardiomyopathy (HCM) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Characteristics

    3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends And Strategies

    4. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Macro Economic Scenario

    4.1. COVID-19 Impact On Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    4.2. Ukraine-Russia War Impact On Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    4.3. Impact Of High Inflation On Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    5. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size And Growth

    5.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segmentation

    6.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Antiarrhythmic Agents

    Anticoagulants

    Beta Adrenergic Blocking Agents

    Calcium Channel Blockers

    Other Drug Types

    6.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Defibrillators

    Pacemakers

    Other Device Types

    6.3. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospitals

    Clinics

    7. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Regional And Country Analysis

    7.1. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    8.1. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    9.1. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    9.2. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    10.1. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    11.1. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    12.1. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    13.1. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    14.1. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    15.1. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    15.2. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    16.1. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    17.1. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    18.4. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    19.1. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    19.2. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    20.1. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    21.1. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    21.2. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    22.1. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    22.2. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    23.1. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    23.2. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    24.1. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    25.1. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    25.2. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    26.1. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

    26.2. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Landscape And Company Profiles

    27.1. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitive Landscape

    27.2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Company Profiles

    27.2.1. Merck & Co. Inc

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Pfizer Inc

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Sanofi S.A.

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Teva Pharmaceutical Industries Ltd

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Novartis AG

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

    29. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Historic And Forecast Inflation Rates

    30.4. Research Inquiries

    30.5. The Business Research Company

    30.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Merck & Co. Inc Financial Performance
  • Table 47: Pfizer Inc Financial Performance
  • Table 48: Sanofi S.A. Financial Performance
  • Table 49: Teva Pharmaceutical Industries Ltd Financial Performance
  • Table 50: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Device Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Merck & Co. Inc Financial Performance
  • Figure 47: Pfizer Inc Financial Performance
  • Figure 48: Sanofi S.A. Financial Performance
  • Figure 49: Teva Pharmaceutical Industries Ltd Financial Performance
  • Figure 50: Novartis AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report